Why study Amyloid Aggregation?
Hallmarks of Alzheimer's neurodegenerative pathology include the production, oligomerization/fibrillation, and deposition of beta-amyloid peptide. Drug discovery for compounds that affect amyloid aggregation are being explored as leads for AD treatment, making it important to have reliable tools such as Aggresure to study amyloidoses.
How is aggregation guaranteed with our AggreSureTM Peptides?
AggreSureTM beta-amyloid (1-42, 1-40) peptides are pre-treated and tested for aggregation using SensoLyte« ThT Aβ42 or Aβ40 Aggregation kits respectively.
Fig 2. Fluorescence signal is correlated with an increase of A▀42 fibril formation. Phenol Red, Morin, Tannic Acid, Dopamine, and o-Vanillin were added at 100ÁM final concentration to inhibit A▀42 aggregation. Fluorescence was monitored at Ex/Em= 440/484 nm every 5 minutes at 37║C with 15 seconds shaking between reads (Flexstation II-384 fluorimeter, Molecular Devices).
Fig 3. Fluorescence signal is correlated with an increase of A▀40 fibril formation. Phenol Red, Morin, Rhodamine B, and Tannic Acid were added at 50 ÁM final concentration to inhibit A▀40 aggregation. Fluorescence was monitored at
Ex/Em= 440/484 nm every 5 minutes at 37║C with 15 seconds shaking between reads (Flexstation II-384 fluorimeter, Molecular Devices).
Cheng, Q. et al (2018). TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant TREM2(R47H) on murine myeloid cell function. J Biol Chrem 293(32):12620-12633. doi: 10.1074/jbc.RA118.001848.
Reinhardt, S. et al. (2018). Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks. Sci Rep 8(1):1329. doi: 10.1038/s41598-018-19577-7.
Maneshi, MM. et al. (2018). Enantiomeric Aβ peptides inhibit the fluid shear stress response of PIEZO1. Sci Rep 8(1):14267. doi: 10.1038/s41598-018-32572-2.
Livadiotis, G. et al (2017). Experimental Analysis of Interacting HT22 Plasma Mrembrane Cholesterol and β-Amyloid. Advances in Alzheimer's Disease 6(04):75.
An, S. et al (2017). Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42. Alzheimers Res Ther 9:86. doi:10.1186/s13195-017-0310-6
Wang, M. et al (2017). Oligomeric forms of amyloid β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Alzheimers Res Ther 9:98. doi:10.1186/s13195-017-0324-0
Hartz. AM, et al. (2016). Aβ40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway. J Neurosci. 36(6):1930-41. doi:10.1523/JNEUROSCI.0350-15.2016.